Kevzara: new SC biologic for moderate to severe RASecond interleukin-6 antagonist for rheumatoid arthritis reaches the Canadian market. New US guidelines for managing acute and recurrent goutOutline preferred treatments for acute gout and the benefits and risks of urate-lowering therapy to prevent recurrent gout. Pharmacist–physician collaborative care preferred in inflammatory arthritis Patient satisfaction superior to traditional physician model in a rheumatology clinic. First subsequent entry biologic for etanercept reaches the Canadian market Merck’s Brenzys approved for use in rheumatoid arthritis and ankylosing spondylitis. Family physicians in N.S. helping rheumatologists and their patients in shared-care model Watch for C. difficile arthritis 5 tips for the safe treatment of acute gout This article provides pharmacists with five important tips for the safe management of an acute gout attack. How to prevent fractures in older adults in long-term care New Canadian guidelines outline prevention strategies for those at high risk of fracture and those not at high risk. Video: A quick refresher on treating osteoarthritis Fibromyalgia: Unravelling the mystery Rheumatologist posits a role for spinal inflammation First Previous 11 12 13 14 15 Next Last
